Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Prothena Corporation PLC | PRTA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 20.41 | 03:09:34 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 20.41 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 19.52 - 73.135 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 20.41 | USD |
Prothena Corporation PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.1B | 53.72M | - | 91.37M | -147.03M | -2.74 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Prothena News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PRTA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.62 | 21.99 | 19.785 | 20.92 | 467,326 | -0.21 | -1.02% |
| 1 Month | 22.57 | 22.91 | 19.52 | 20.96 | 425,885 | -2.16 | -9.57% |
| 3 Months | 25.82 | 26.36 | 19.52 | 22.14 | 503,298 | -5.41 | -20.95% |
| 6 Months | 40.00 | 41.545 | 19.52 | 28.44 | 675,244 | -19.59 | -48.98% |
| 1 Year | 68.04 | 73.135 | 19.52 | 36.92 | 620,309 | -47.63 | -70.00% |
| 3 Years | 56.22 | 79.749 | 19.52 | 44.71 | 530,301 | -35.81 | -63.70% |
| 5 Years | 9.52 | 79.749 | 6.44 | 37.01 | 429,894 | 10.89 | 114.39% |
Prothena Description
| Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |
